Monthly Intravenous Cyclophosphamide Dosing for Adults
For ANCA-associated vasculitis (AAV) in adults, administer intravenous cyclophosphamide at 15 mg/kg at weeks 0,2,4,7,10, and 13, with potential extension to weeks 16,19,21, and 24 if needed for ongoing disease activity. 1
Standard Dosing Protocol
The KDIGO 2024 guideline provides the most current evidence-based dosing schedule for monthly IV cyclophosphamide 1:
- Initial intensive phase: 15 mg/kg every 2 weeks for 3 doses (weeks 0,2,4)
- Maintenance phase: 15 mg/kg every 3 weeks for at least 3 doses (weeks 7,10,13)
- Extended treatment: Continue to weeks 16,19,21, and 24 if disease activity persists
- Total duration: 3-6 months maximum
This regimen differs from the older "monthly" terminology because it actually involves more frequent dosing initially (every 2 weeks), then transitions to every 3 weeks—not strictly monthly intervals.
Age-Based Dose Reductions
Critical adjustments are mandatory for older patients 1:
- Age 60 years: Reduce to 12.5 mg/kg per dose
- Age 70 years: Reduce to 10 mg/kg per dose
- GFR <30 ml/min/1.73 m²: Further reduce by 2.5 mg/kg per dose
These reductions are essential to prevent severe myelosuppression and infections in vulnerable populations.
Alternative Dosing Considerations
The ACR/Vasculitis Foundation 2021 guideline mentions "intermittent 15 mg/kg (IV) every 2 weeks for 3 doses, followed by 15 mg/kg (IV) every 3 weeks for at least 3 doses" 2, which aligns with the KDIGO protocol. However, some older protocols used 500-750 mg/m² monthly for 6 months 3, but this is not the preferred contemporary approach for AAV.
Common Pitfalls to Avoid
Do not use body surface area (mg/m²) dosing for AAV—the guideline-recommended approach uses weight-based dosing (mg/kg) 1
Do not continue beyond 6 months for induction therapy—prolonged exposure increases toxicity without additional benefit 1
Do not skip age-based dose reductions—failure to adjust increases risk of life-threatening infections and myelosuppression 1
Ensure adequate hydration and morning administration to reduce hemorrhagic cystitis risk 4
Monitoring Requirements
Before each dose, verify 4:
- Neutrophils >1,500/mm³
- Platelets >50,000/mm³
- No active serious infection
Hold or reduce dosing if these thresholds are not met, as severe myelosuppression can lead to sepsis and death 4.
Context-Specific Variations
For lupus nephritis, older protocols used 500-750 mg/m² monthly for 6 months 5, 3, but this differs from AAV management. For nephrotic syndrome in children, oral daily dosing is used instead 4. The question appears to reference AAV given the context, where the KDIGO 2024 protocol is the current standard 1.